We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$26.2B
AUM Growth
+$914M
(+3.6%)
Cap. Flow
+$1.01B
Cap. Flow
% of AUM
3.87%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
1,591
New
69
Increased
817
Reduced
431
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$107M |
| 2 |
EXL Service
EXLS
|
+$72M |
| 3 |
Apple
AAPL
|
+$64.3M |
| 4 |
Synopsys
SNPS
|
+$56.8M |
| 5 |
ServiceNow
NOW
|
+$54.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$74.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$53.5M |
| 3 |
Edwards Lifesciences
EW
|
+$45M |
| 4 |
Abbott
ABT
|
+$40.3M |
| 5 |
Rockwell Automation
ROK
|
+$39.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.4% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 12.04% |
| 4 | Communication Services | 9.47% |
| 5 | Industrials | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Toll Brothers
TOL
$14B
| $3.27M | 0.01% |
26,000
+3,800
| +17% | +$564K |
|
527
East-West Bancorp
EWBC
$18.6B
| $3.27M | 0.01% |
34,100
+3,200
| +10% | +$314K |
|
528
RenaissanceRe
RNR
$13.3B
| $3.26M | 0.01% |
13,100
+800
| +7% | +$215K |
|
529
EPAM Systems
EPAM
$5.24B
| $3.23M | 0.01% |
13,800
+4,749
| +52% | +$1.06M |
|
530
J.M. Smucker
SJM
$12.9B
| $3.23M | 0.01% |
29,300
-17,872
| -38% | -$2.06M |
|
531
BioMarin Pharmaceuticals
BMRN
$13.3B
| $3.21M | 0.01% |
48,900
-75,122
| -61% | -$5.03M |
|
532
Blue Owl Capital
OWL
$19.7B
| $3.21M | 0.01% |
138,000
+7,700
| +6% | +$176K |
|
533
Bio-Techne
TECH
$11.2B
| $3.19M | 0.01% |
44,348
-248,400
| -85% | -$18.2M |
|
534
Okta
OKTA
$26.9B
| $3.19M | 0.01% |
40,500
-11,895
| -23% | -$922K |
|
535
NIO
NIO
$11.3B
| $3.17M | 0.01% |
726,014
+157,333
| +28% | +$801K |
|
536
Gen Digital
GEN
$17.7B
| $3.16M | 0.01% |
115,552
+6,440
| +6% | +$185K |
|
537
Vipshop
VIPS
$6.8B
| $3.15M | 0.01% |
234,148
+13,355
| +6% | +$192K |
|
538
Arcos Dorados Holdings
ARCO
$1.71B
| $3.15M | 0.01% |
432,330
-87,400
| -17% | -$749K |
|
539
XP
XP
$8.18B
| $3.13M | 0.01% |
264,231
-49,500
| -16% | -$779K |
|
540
Insmed
INSM
$27.6B
| $3.13M | 0.01% |
45,281
+1,700
| +4% | +$122K |
|
541
AngloGold Ashanti
AU
$48.1B
| $3.12M | 0.01% |
135,064
+15,564
| +13% | +$407K |
|
542
Duolingo
DUOL
$6.74B
| $3.11M | 0.01% |
9,600
-400
| -4% | -$127K |
|
543
Allegion
ALLE
$14.2B
| $3.11M | 0.01% |
23,800
+3,100
| +15% | +$439K |
|
544
Sarepta Therapeutics
SRPT
$1.95B
| $3.1M | 0.01% |
25,515
+1,700
| +7% | +$208K |
|
545
Nordson
NDSN
$17.3B
| $3.08M | 0.01% |
14,730
+1,100
| +8% | +$272K |
|
546
Lamar Advertising Co
LAMR
$15.8B
| $3.04M | 0.01% |
24,981
-1,000
| -4% | -$131K |
|
547
Rollins
ROL
$17.4B
| $3.02M | 0.01% |
65,241
+10,217
| +19% | +$500K |
|
|
BCYC
548
Bicycle Therapeutics
BCYC
$279M
| $3.02M | 0.01% |
215,900
-2,800
| -1% | -$60K |
|
549
Boston Properties
BXP
$11B
| $3.02M | 0.01% |
40,600
-600
| -1% | -$48.7K |
|
550
Lennar Class B
LEN.B
$20.7B
| $3.01M | 0.01% |
23,990
-17,026
| -42% | -$2.56M |
|
Similar funds
GAM
Handelsbanken Fonder's Q4 2024 Portfolio in Review
As of Q4 2024, Handelsbanken Fonder held 1,591 positions worth $26.2B, up 3.6% from $25.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Handelsbanken Fonder deployed $1.01B of net new capital in Q4 2024, opening 69 new positions and adding to 817 existing holdings. Its largest new stake was GE Vernova: 105,537 shares worth $34.7M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Halozyme, an estimated $74.5M trimmed.
- Handelsbanken Fonder's largest Q4 2024 buy was GE Vernova: 105,537 shares worth $34.7M.
- Handelsbanken Fonder added most to Microsoft in Q4 2024, an estimated $107M increase.
- Handelsbanken Fonder's biggest Q4 2024 reduction was Halozyme, cutting an estimated $74.5M.
- Handelsbanken Fonder fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $5.92M.
- Handelsbanken Fonder's ten largest holdings make up 33% of its $26.2B portfolio in Q4 2024.
- Handelsbanken Fonder opened 69 new positions and closed 49 in Q4 2024.
- Handelsbanken Fonder's portfolio value rose 3.6% quarter-over-quarter to $26.2B.
Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.